Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.

Bibliographic Details

Main Authors:	Reis Neto,Edgard Torres dos, Kakehasi,Adriana Maria, Pinheiro,Marcelo de Medeiros, Ferreira,Gilda Aparecida, Marques,Cláudia Diniz Lopes, Mota,Licia Maria Henrique da, Paiva,Eduardo dos Santos, Pileggi,Gecilmara Cristina Salviato, Sato,Emília Inoue, Reis,Ana Paula Monteiro Gomides, Xavier,Ricardo Machado, Provenza,José Roberto
Format:	Digital revista
Language:	English
Published:	Sociedade Brasileira de Reumatologia 2020
Online Access:	http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100302
Tags:	Add Tag No Tags, Be the first to tag this record!